TEVA Teva Pharmaceutical Industries Ltd
Price Chart
Executive Summary
Teva presented new IMPACT-TD Registry data at the 2026 APA Annual Meeting, revealing that 85% of young adults (18-29) with mood disorders and tardive dyskinesia experience moderate-to-severe impact, yet only 23% received a formal diagnosis. The data highlights a significant diagnostic gap and underscores Teva's commitment to TD research, but the press release contains no financial figures, no regulatory decision, and no change to Teva's commercial outlook.
Actionable Insight
This press release is a routine clinical data presentation with no immediate financial or regulatory catalyst for Teva. Traders should monitor for any future regulatory actions or label expansions related to TD treatments, but no near-term stock-moving event is indicated.
Key Facts
- New IMPACT-TD Registry data presented at APA 2026 shows 85% of young adults (18-29) with mood disorders and TD experience moderate-to-severe impact.
- Only 23% of young adults (18-29) with TD received a formal diagnosis, revealing a diagnostic gap.
- Average delay in TD diagnosis is more than 3.5 years after involuntary movements are first recognized.
- The IMPACT-TD Registry is a 3-year, prospective, Phase 4 study with 611 participants.
- No financial data, revenue figures, or changes to Teva's product pipeline were disclosed in the press release.
Financial Impact
No financial impact disclosed; the press release is a clinical data update with no revenue or earnings implications.
Risk Factors
- No new commercial or regulatory catalyst; the data does not change Teva's near-term revenue or earnings outlook.
- Diagnostic gap findings may not translate into increased prescribing or market share for Teva's TD treatments.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3296535 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
4d ago
|
Press Release
| $34.04 awaiting T+5 | awaiting T+5 | — | $34.63 (+1.75%) |
|
Jun 8, 2026
6d ago
|
Insider Cluster
| $33.26 awaiting T+5 | awaiting T+5 | — | $34.63 (+4.12%) |
|
Jun 5, 2026
9d ago
|
Press Release
| $34.30 awaiting T+5 | awaiting T+5 | — | $34.63 (+0.96%) |
|
May 18, 2026
27d ago
|
Insider Cluster
| $34.07 $34.43 | ▲ +1.04% | ▼ −1.25% | $34.63 (+1.64%) |
|
May 18, 2026
27d ago
|
Press Release
| $34.03 $34.61 | ▲ +1.70% | ▲ +0.09% | $34.63 (+1.77%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $35.39 $36.23 | ▲ +2.37% | ▼ −0.74% | $34.63 (−2.14%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $35.39 $36.23 | ▲ +2.37% | ▼ −0.74% | $34.63 (−2.14%) |
|
Apr 16, 2026
8w ago
|
Court Ruling
| $31.26 $31.20 | ▼ −0.19% | ▼ −1.18% | $34.63 (+10.79%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $28.70 $28.73 | ▲ +0.11% | ▲ +2.26% | $34.63 (+20.68%) |
|
Feb 28, 2026
15w ago
|
Institutional Cluster
| $33.76 $31.50 | ▼ −6.69% | ▼ −5.48% | $34.63 (+2.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access